Cognition Therapeutics, Inc. (NASDAQ: CGTX) is
presenting in vivo preclinical results at the Society for
Neuroscience’s annual meeting illuminating the role of sigma-2
(σ-2) receptor modulators, including CT1812, in models of
Alzheimer's and Parkinson’s diseases.
The effect of two chemically distinct σ-2 receptor modulators in
a mouse model of Alzheimer’s disease on gene and protein expression
are presented. Data shed light on the molecular mechanisms and
build upon previous studies in this same mouse model where
Cognition’s lead candidate, CT1812 was previously shown to decrease
binding of Aβ oligomers to neuronal synapses and ameliorate
cognitive deficits.
Separately, work supported by a Michael J. Fox Foundation grant
award is presented defining the impact of σ-2 receptor modulators
on gene and protein expression. In two different rat models of
Parkinson’s disease, the same two σ-2 receptor modulators are shown
to effect pathways associated with Parkinson's disease, including
cell survival, metabolism, autophagy, and protein/lipid
transport.
Mary Hamby, Ph.D., Cognition’s VP of research, explained, “These
findings help to broaden our understanding of the role of the σ-2
receptor in central nervous system diseases, and support continued
discovery and development of candidates that modulate this
therapeutic target for Alzheimer’s disease, dementia with Lewy
bodies, and Parkinson’s disease.”
Poster details:Title: A transcriptomic analysis
to investigate the role of sigma-2 receptor modulators CT1812 and
CT2168 in a mouse model of Alzheimer’s diseaseAuthors: Caldwell J,
Cho E, Knezovich N, Caggiano AO, Di Caro V, Hamby MESession: Nov 15
- Session PSTR527 - Alzheimer's Disease and Dementia: Genomics and
Other Omics Approaches
Title: A proteomic analysis to elucidate the role of sigma-2
receptor modulators CT1812 and CT2168 in a mouse model of
Alzheimer’s diseaseAuthors: Cho E, Caldwell J, Pandey K, Duong DM,
Seyfried NT, Caggiano AO, Di Caro V, Hamby MESession: Nov 15 -
Session PSTR527 - Alzheimer's Disease and Dementia: Genomics and
Other Omics Approaches
Title: Exploratory omics study reveals potential roles of
sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of
Parkinson’s diseaseAuthors: Reaver AJ, Lizama BN, Pandey K, Duong
DM, Seyfried NT, Caggiano AO, Hamby MESession: Nov 14 - PSTR402 -
Therapeutic Strategies: Small Molecule Therapeutics
Title: Unbiased proteomic and transcriptomic analysis of Sigma-2
receptor modulation in an in vivo model of synucleinopathyAuthors:
Lizama BN, Reaver AJ, Pandey K, Duong DM, Seyfried NT, Caggiano AO,
Hamby MESession: Nov 14 - PSTR402 - Therapeutic Strategies: Small
Molecule Therapeutics
About Cognition Therapeutics, Inc.Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical programs in
Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry
age-related macular degeneration (dry AMD). We believe CT1812 and
our pipeline of σ-2 receptor modulators can regulate pathways that
are impaired in these diseases. We believe that targeting the σ-2
receptor with CT1812 represents a mechanism functionally distinct
from other current approaches in clinical development for the
treatment of degenerative diseases. More about Cognition
Therapeutics and its pipeline can be found
at https://cogrx.com
Forward Looking Statements This press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release, other than statements of
historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding our product candidates, including CT1812, and any
expected or implied benefits or results, including that initial
clinical results observed with respect to CT1812 will be replicated
in later trials and our clinical development plans, including
statements regarding our clinical studies of CT1812 in animal
models and any analyses of the results therefrom, are
forward-looking statements. These statements, including statements
relating to the timing and expected results of our clinical trials
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “forecast,” “potential” or “continue” or the
negative of these terms or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: competition; our ability to secure new (and retain existing)
grant funding; our ability to grow and manage growth, maintain
relationships with suppliers and retain our management and key
employees; our ability to successfully advance our current and
future product candidates through development activities,
preclinical studies and clinical trials and costs related thereto;
uncertainties inherent in the results of preliminary data,
pre-clinical studies and earlier-stage clinical trials being
predictive of the results of early or later-stage clinical trials;
the timing, scope and likelihood of regulatory filings and
approvals, including regulatory approval of our product candidates;
changes in applicable laws or regulations; the possibility that the
we may be adversely affected by other economic, business or
competitive factors, including ongoing economic uncertainty; our
estimates of expenses and profitability; the evolution of the
markets in which we compete; our ability to implement our strategic
initiatives and continue to innovate our existing products; our
ability to defend our intellectual property; the impact of the
COVID-19 pandemic on our business, supply chain and labor force;
and the risks and uncertainties described more fully in the “Risk
Factors” section of our annual and quarterly reports filed with
the Securities & Exchange Commission and are available at
www.sec.gov. These risks are not exhaustive, and we face both known
and unknown risks. You should not rely on these forward-looking
statements as predictions of future events. The events and
circumstances reflected in our forward-looking statements may not
be achieved or occur, and actual results could differ
materially from those projected in the forward-looking statements.
Moreover, we operate in a dynamic industry and economy. New risk
factors and uncertainties may emerge from time to time, and it is
not possible for management to predict all risk factors and
uncertainties that we may face. Except as required by applicable
law, we do not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
Contact
Information: Cognition Therapeutics, Inc.
info@cogrx.com |
Casey McDonald
(media) Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com |
Daniel Kontoh-Boateng
(investors) Tiberend Strategic Advisors, Inc.
dboateng@tiberend.com |
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From Apr 2024 to May 2024
Cognition Therapeutics (NASDAQ:CGTX)
Historical Stock Chart
From May 2023 to May 2024